LH
Heads-up: USD ADP Nonfarm Employment Change is due in 13 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD ISM Non-Manufacturing Prices Paid is due in 15 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD ISM Non-Manufacturing PMI is due in 15 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD EIA Crude Oil Stocks Change is due in 15 h (high impact). The outlook can shift noticeably around it.
- Q3 2026 earnings released via 8-K; reaction to consensus is the dominant near-term catalyst, with support/resistance noted near $230-$240.
- First-to-market FDA-approved BD Onclarity HPV Assay, including self-collection, broadens the diagnostic portfolio and revenue potential.
- Acquisition of BioReference Health assets for over $722M plus a steady $0.72 quarterly dividend underscore expansion and shareholder return priorities.
- Raised 2026 guidance from late July, but YTD underperformance vs Quest (which has rallied 41%) shows relative sector pressure.
News situation · 4 items / 30 D
3 of 4 straight from the issuer or regulator
The fundamental picture for Labcorp is constructive, though the lack of active technical signals means this view rests entirely on strategic and operational drivers. The most immediate catalyst is the October 28 Q3 earnings print, formally disclosed via an 8-K filing; the stock's direction depends on how results compare with analyst consensus, and the $230-$240 zone is flagged as a
Read full analysis
near-term pivot. Beyond the print, the first-to-market rollout of the FDA-approved BD Onclarity HPV Assay, with self-collection options, should broaden patient access and support revenue growth. The planned acquisition of select BioReference Health assets for over $722 million expands the diagnostic footprint, while the maintained $0.72 quarterly dividend signals steady capital return. Management raised 2026 guidance in late July after a Q2 beat, reflecting confidence in testing volumes and operational efficiencies. However, there are clear counterweights: Labcorp has underperformed Quest Diagnostics year to date, and integration risks accompany both the HPV assay and the BioReference deal. The macro backdrop features a cluster of high-impact USD releases, including GDP, jobless claims, and PCE data released roughly 12 hours ago; with no outcome figures provided, these only form a neutral backdrop. Upcoming high-impact data—ISM manufacturing, JOLTS, ADP, ISM non-manufacturing, and crude oil stocks—arrive in the coming days and could shift sentiment, but they do not imply a fixed direction for this stock.
Supporting factors
- First commercial laboratory to offer the FDA-approved BD Onclarity HPV Assay, including self-collection, driving portfolio expansion and patient access.
- Acquisition of select BioReference Health assets for over $722 million, scaling diagnostic capabilities and market presence.
- Quarterly dividend of $0.72 per share maintained, reinforcing shareholder return policy.
- Raised 2026 earnings guidance from late July, tied to robust testing volumes and operational efficiencies.
Risks and what to watch
- Q3 earnings could miss analyst consensus; the 8-K release may trigger volatility around the $230-$240 support/resistance zone.
- Integration challenges from the BioReference acquisition and HPV assay rollout could slow expected benefits.
- Quest Diagnostics' 41% YTD rally highlights competitive pressure; Labcorp's relative underperformance may persist.
- Upcoming high-impact USD data (ISM manufacturing, JOLTS, ADP, ISM non-manufacturing) in the coming days pose event risk, though no fixed direction is implied.
What does the 8-K filing on October 28 mean for Labcorp's near-term trading?
The 8-K filing formally discloses Q3 2026 results. The market reaction will hinge on whether these results beat, match, or miss analyst consensus. Since the filing is the official data source, expect heightened volatility around the release. The note that the $230-$240 level is a near-term support/resistance zone suggests traders may watch price action around that band. No directional call is made here; the outcome depends on the numbers relative to expectations.
How significant is the BD Onclarity HPV Assay rollout for Labcorp's growth?
The rollout is a first-to-market move: Labcorp is the first commercial laboratory to offer the FDA-approved assay, including self-collection options. This broadens patient access across clinician-collected and at-home modalities, which could drive revenue growth across its network. The catalyst is considered bullish and moderate impact, but integration into existing workflows and any regulatory hurdles around self-collection standards are risks. Over the mid-term, execution on this expansion is a key driver alongside the BioReference acquisition.
Why does Labcorp's stock performance lag Quest Diagnostics year to date?
The input notes that Quest Diagnostics has rallied 41% year to date, while Labcorp has underperformed. This relative divergence is attributed to sector-wide competitive dynamics, though specific reasons are not detailed. Labcorp's recent strategic moves—the HPV assay, BioReference acquisition, and raised guidance—are positive, but the market may be rewarding Quest more for its own momentum. This underperformance is a risk that could cap sentiment even if Labcorp's fundamentals improve.
What should be watched around the upcoming USD economic releases?
Several high-impact USD releases are due in the coming days: ISM Manufacturing Prices Paid and PMI in 3 days, then JOLTS, ADP Nonfarm Employment, ISM Non-Manufacturing prices/PMI, and crude oil stocks within 4-6 days. These are macro backdrop for Labcorp, but do not dictate a fixed direction. They could shift overall market sentiment and risk appetite, which may indirectly affect equities. The FOMC press conference from 30 hours ago is also part of the recent context, though its outcome isn't provided. Given the absence of actual figures, no direct link to Labcorp is made.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
LH fundamental outlook?
From news analysis — different time windows than the trading horizons above
Attention will fixate on the Q3 earnings print and management guidance, with the 8-K release providing the official data. Expect heightened volatility around the October 28 release; the stock's direction depends on beats/misses relative to consensus. Watch the $230-$240 level as a near-term support/resistance zone.
The HPV assay rollout and integration of BioReference assets will be the primary drivers over the next month. Execution on these expansion initiatives could support revenue growth and market share gains. However, sector-wide competitive dynamics, notably Quest's outperformance, may cap sentiment.
Structural drivers such as the aging population, increased focus on preventive care, and the adoption of self-collection diagnostics support long-term demand for Labcorp's services. Successful integration of acquisitions and continued innovation in diagnostics will be key to sustaining growth. Guidance likely to be revisited in early 2027; current outlook remains constructive.
Economic data for LH
Full calendarRecently released
- TodayUSDJOLTS Job Openings●●●Forecast 6.779MPrevious 7.079M
- November 2, 2026USDISM Manufacturing Prices Paid●●●Forecast 80.7Previous 77.9
- November 2, 2026USDISM Manufacturing PMI●●●Forecast 54.7Previous 54.5
Coming up
- TomorrowUSDADP Nonfarm Employment Change●●●Forecast 64KPrevious 90Kin 13h
- TomorrowUSDISM Non-Manufacturing Prices Paid●●●Forecast 69.5Previous 74.0in 15h
- TomorrowUSDISM Non-Manufacturing PMI●●●Forecast 55.2Previous 54.9in 15h
- TomorrowUSDEIA Crude Oil Stocks Change●●●in 15h
- November 5, 2026USDInitial Jobless Claims●●●in 1 day
- November 6, 2026USDUnemployment Rate●●●Forecast 4.2%Previous 4.2%in 2 days
- November 6, 2026USDAverage Hourly Earnings m/m●●●Forecast 0.2%Previous 0.1%in 2 days
- November 6, 2026USDNonfarm Payrolls●●●Forecast 55KPrevious 29Kin 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
What is being reported about LH
📝 Overview Generated automatically?
LH has been the subject of 7 signals across 7 articles in the last 365 days. Sentiment skews Neutral (71%).
Breakdown: 2 bullish, 0 bearish, 5 neutral. AI confidence averages 66% across all signals.
Most-cited catalysts: Raised full-year 2026 EPS guidance above consensus estimates (1×), Strong Q2 results with volume growth across routine and specialty testing (1×), Acquisition of select BioReference Health assets for over $722 million (1×). Most-cited risk factors: Potential moderation in testing volumes if healthcare utilization normalizes (1×), Competitive pressures from other diagnostic firms (1×), Integration challenges associated with absorbing new diagnostic assets (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.